Mobile website
Clinical Research
Relationship of RASSF1A promoter methylation with expressions of Cyclin D1 and P53 in colorectal cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To examine RASSF1A promoter methylation and Cyclin D1 and P53 expressions in colorectal cancer tissues, and to analyze their relationship with the clinicopathologic characteristics of colorectal cancer. Methods: Thirty-seven colorectal cancer and 14 peri-cancer tissue samples were obtained from Changhai Hospital during Aug. 2008 to Aug. 2009. RASSF1A promoter methylation in colorectal cancer tissues was detected by methylation-specific PCR (MSP); expressions of Cyclin D1 and P53 in colorectal cancer tissues were examined by immunohistochemistry assay. The relationship among RASSF1A promoter methylation, Cyclin D1 and P53 expressions and their relationship with clinicpathologic characteristics of colorectal cancer was analyzed. Results: Methylation of RASSF1A promoter was found 23(6216%) of the 37 colorectal cancer tissues and 12 (85.71%)of the 14 peri-cancer tissues; 14 (37.84%) of the 37 colorectal cancer tissues had Cyclin D1 expression and 15 (40.54%) had P53 expression. Cyclin D1 and P53 expressions was negative in 14 peri-cancer tissues. RASSF1A promoter methylation rate in rectum cancer was higher than that in the colon cancer (P<0.05). Cyclin D1 expression was negatively correlated with patient age (P<0.05), and P53 expression was positively correlated with lymph node metastasis (P<0.05); RASSF1A promoter methylation had no relationship with Cyclin D1 or P53 expressions (P>0.05). Conclusion: Combined detection of RASSF1A promoter methylation, Cyclin D1 and P53 expressions may lay a foundation for studying development and progression of colorectal cancer.
Keywords:
Project Supported:
Project supported by the Key Research Foundation from Health Bureau of Hongkou District of Shanghai \[No. (2007)151\]
Clc Number:
